Multi-Cancer
How Revonco works?
1
3
4
2
Every cell shed particles including their DNA in the blood stream when they die. Cancerous cells do the same.
Single Blood Draw
Our kits keep the samples stable for 7 days at room temperature, so the blood draw can be performed anywhere from the clinics to at-home phlebotomy service to the most remote places. Perfect for national scale screening.
Preparing cfDNAs
We separate plasma, where the cfDNAs are, and prepare them to be sequenced and target the informative ones with our proprietary enrichment panel. The enrichment panel reduce the sequencing cost by more than 10x.
Sequencing
We use advanced NGS technology to sequence the genetic and epigenetic codes from the cfDNAs. Epigenetic codes are molecular switches that influence cells type and function and can determine if a cell is cancerous.
REVONCO AI
Our proprietary AI technology, uses genetic and epigenetic codes to find a few cfDNA that comes from cancer cells to detect cancer. If cancer signature is detected, it also reports where in the body that cancer cells are.
REVONCO by Detectiome
Game changing performance
Revonco Multi-Cancer Early Detection provides a simple blood test that detects multiple cancers at their earliest stage, with its level of detection (LOD) at less than 1 in 10,000 cfDNA from cancer cells.
Why Multi-Cancer Early Detection?
VS
Conventional Screening*
Number of cancers types detected
10+
1
percent of cancer mortality influenced
90+%
2-9%
False cancer signal per one true cancer detected
1
4-7
Positive Likelihood Ratio
45
4-8
*Mammography (breast cancer), Colonoscopy (colorectal cancer), Digital Rectal Exam (prostate cancer), Pap Smear (cervical cancer)
data from SEER and cancer.gov
Experts view
"Multi-cancer early detection represents a paradigm shift in how cancers will be diagnosed and treated in the future."
"The science is fascinating and there is a real opportunity here. The question is how do we accelerate MCED so it improves patients’ lives and aligns with patient values."
Brian Druker, M.D.
Director of the OHSU Knight Cancer Institute
Join us in advancing cancer care.
To run a pilot study to see the power of Revonco and Multi-Cancer Early Detection, or use Revonco in your research or clinical trial
Contact us today
It's my hope that one day, we will be able to use MCED tests to cure more cancer and dramatically reduce the toll of cancer worldwide.
Jyoti Patel, M.D.
Medical Director of Thoracic Oncology and Assistant Director for Clinical Research at the Lurie Cancer Center of Northwestern University
Cancer doctors, care providers and payers need to get ready for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accuracy of multi-cancer early detection (MCED) blood testing, presented at the ESMO Congress 2022, have major implications for future cancer care provision.
Fabrice André
Director of Research at Gustave Roussy Cancer Centre, Villejuif, France and newly elected future president of the Society for the years 2025-2026
The results are an important first step for early cancer detection tests because they showed a good detection rate for people who had cancer and an excellent specificity rate for those who did not have cancer. In people with a positive test, it took less than two months to confirm the diagnosis if they had cancer and it took a bit longer if they did not have cancer primarily because physicians opted to perform imaging studies and then repeat them a second time several months later to investigate the possibility of a cancer diagnosis,
Deb Schrag
Oncologist at Memorial Sloan Kettering Cancer Center, New York, USA
In The Media
